Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4

Emily Y. Chew, John Paul SanGiovanni, Frederick L. Ferris, W. T. Wong, Elvira Agron, Traci E. Clemons, Robert Sperduto, Ronald Danis, Suresh R. Chandra, Barbara A. Blodi, Amitha Domalpally, Michael J. Elman, Andrew N. Antoszyk, Alan J. Ruby, David Orth, Susan B. Bressler, Gary E. Fish, George B. Hubbard, Michael L. Klein, Thomas R. FribergPhilip J Rosenfeld, Cynthia A. Toth, Paul Bernstein

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Importance Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES Cataract surgerywas documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95%CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95%CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95%CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.

Original languageEnglish
Pages (from-to)843-850
Number of pages8
JournalJAMA Ophthalmology
Volume131
Issue number7
DOIs
StatePublished - Jul 1 2013

Fingerprint

Lutein
Eye Diseases
Cataract
Therapeutics
Macular Degeneration
Zeaxanthins
Pseudophakia
Aphakia
Vision Disorders
Unsaturated Fatty Acids
Telephone
Visual Acuity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Chew, E. Y., SanGiovanni, J. P., Ferris, F. L., Wong, W. T., Agron, E., Clemons, T. E., ... Bernstein, P. (2013). Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology, 131(7), 843-850. https://doi.org/10.1001/jamaophthalmol.2013.4412

Lutein/zeaxanthin for the treatment of age-related cataract : AREDS2 randomized trial report no. 4. / Chew, Emily Y.; SanGiovanni, John Paul; Ferris, Frederick L.; Wong, W. T.; Agron, Elvira; Clemons, Traci E.; Sperduto, Robert; Danis, Ronald; Chandra, Suresh R.; Blodi, Barbara A.; Domalpally, Amitha; Elman, Michael J.; Antoszyk, Andrew N.; Ruby, Alan J.; Orth, David; Bressler, Susan B.; Fish, Gary E.; Hubbard, George B.; Klein, Michael L.; Friberg, Thomas R.; Rosenfeld, Philip J; Toth, Cynthia A.; Bernstein, Paul.

In: JAMA Ophthalmology, Vol. 131, No. 7, 01.07.2013, p. 843-850.

Research output: Contribution to journalArticle

Chew, EY, SanGiovanni, JP, Ferris, FL, Wong, WT, Agron, E, Clemons, TE, Sperduto, R, Danis, R, Chandra, SR, Blodi, BA, Domalpally, A, Elman, MJ, Antoszyk, AN, Ruby, AJ, Orth, D, Bressler, SB, Fish, GE, Hubbard, GB, Klein, ML, Friberg, TR, Rosenfeld, PJ, Toth, CA & Bernstein, P 2013, 'Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4', JAMA Ophthalmology, vol. 131, no. 7, pp. 843-850. https://doi.org/10.1001/jamaophthalmol.2013.4412
Chew, Emily Y. ; SanGiovanni, John Paul ; Ferris, Frederick L. ; Wong, W. T. ; Agron, Elvira ; Clemons, Traci E. ; Sperduto, Robert ; Danis, Ronald ; Chandra, Suresh R. ; Blodi, Barbara A. ; Domalpally, Amitha ; Elman, Michael J. ; Antoszyk, Andrew N. ; Ruby, Alan J. ; Orth, David ; Bressler, Susan B. ; Fish, Gary E. ; Hubbard, George B. ; Klein, Michael L. ; Friberg, Thomas R. ; Rosenfeld, Philip J ; Toth, Cynthia A. ; Bernstein, Paul. / Lutein/zeaxanthin for the treatment of age-related cataract : AREDS2 randomized trial report no. 4. In: JAMA Ophthalmology. 2013 ; Vol. 131, No. 7. pp. 843-850.
@article{f7c107bbbcee4e6b809ac94d18cceab9,
title = "Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4",
abstract = "Importance Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES Cataract surgerywas documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24{\%}. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95{\%}CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95{\%}CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95{\%}CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.",
author = "Chew, {Emily Y.} and SanGiovanni, {John Paul} and Ferris, {Frederick L.} and Wong, {W. T.} and Elvira Agron and Clemons, {Traci E.} and Robert Sperduto and Ronald Danis and Chandra, {Suresh R.} and Blodi, {Barbara A.} and Amitha Domalpally and Elman, {Michael J.} and Antoszyk, {Andrew N.} and Ruby, {Alan J.} and David Orth and Bressler, {Susan B.} and Fish, {Gary E.} and Hubbard, {George B.} and Klein, {Michael L.} and Friberg, {Thomas R.} and Rosenfeld, {Philip J} and Toth, {Cynthia A.} and Paul Bernstein",
year = "2013",
month = "7",
day = "1",
doi = "10.1001/jamaophthalmol.2013.4412",
language = "English",
volume = "131",
pages = "843--850",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Lutein/zeaxanthin for the treatment of age-related cataract

T2 - AREDS2 randomized trial report no. 4

AU - Chew, Emily Y.

AU - SanGiovanni, John Paul

AU - Ferris, Frederick L.

AU - Wong, W. T.

AU - Agron, Elvira

AU - Clemons, Traci E.

AU - Sperduto, Robert

AU - Danis, Ronald

AU - Chandra, Suresh R.

AU - Blodi, Barbara A.

AU - Domalpally, Amitha

AU - Elman, Michael J.

AU - Antoszyk, Andrew N.

AU - Ruby, Alan J.

AU - Orth, David

AU - Bressler, Susan B.

AU - Fish, Gary E.

AU - Hubbard, George B.

AU - Klein, Michael L.

AU - Friberg, Thomas R.

AU - Rosenfeld, Philip J

AU - Toth, Cynthia A.

AU - Bernstein, Paul

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Importance Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES Cataract surgerywas documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95%CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95%CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95%CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.

AB - Importance Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES Cataract surgerywas documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95%CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95%CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95%CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.

UR - http://www.scopus.com/inward/record.url?scp=84880312820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880312820&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2013.4412

DO - 10.1001/jamaophthalmol.2013.4412

M3 - Article

C2 - 23645227

AN - SCOPUS:84880312820

VL - 131

SP - 843

EP - 850

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 7

ER -